The idea to let Medicare negotiate drug prices has been kicked around for years, but a number of forces have prevented any legislation from being passed, explained Tricia Neuman, ScD, director of the Kaiser Family Foundation's Program on Medicare Policy and the Project on Medicare's Future.
The idea to let Medicare negotiate drug prices has been kicked around for years, but a number of forces have prevented any legislation from being passed, explained Tricia Neuman, ScD, director of the Kaiser Family Foundation's Program on Medicare Policy and the Project on Medicare's Future.
Transcript (modified)
Presidential candidates Hillary Clinton, Senator Bernie Sanders (I-VT), and Donald Trump have all called for Medicare to be able to negotiate drug prices. What has prevented such a policy from being implemented?
This is an idea that has been kicked around for a long time. People in Washington and elsewhere have been talking about the government doing more to negotiate lower drug costs, specifically leveraging lower drug costs for people on Medicare. Honestly, people have been talking about it for at least a decade.
There are a lot of issues that are involved in this sort of broad idea, however. How would this happen? For example, would this be for all drugs that are covered by Medicare? would it be for a subset of drugs? And I think at this point it’s sort of a general feeling that something should be done about drug spending, but we won’t know the impact until these policies get better defined.
In the past, the Congressional Budget Offices looked at this idea of government negotiations and their view is that it might have a negligible effect on spending unless the proposal has real teeth. Which is to say, the government would set a formulary, the government would decide what the cost-sharing would be, and most importantly the government would be willing to walk away from the table if they couldn’t get a better drug price from the pharmaceutical companies.
So this is a big idea, and I think the question is: what are the specifics underneath this broad idea? Of course there are big political forces and major stakeholders engaged in this debate, which is why it hasn’t happened so far.
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More